The reason I mentioned licensing is that one has to ask yourself if the company wants to go through the expense of new plant and equipment for the N assay or let someone else who has the capability and distribution produce and sell it. Hubbard could still be the hub for the flat pack. Investor interest mentioned could have to do with expanding for the flat pack. If the company could get a licensing deal with a big pharma company, this could get out with lightening speed. Just a thought.